AUTHORS
June-Wha Rhee, MD, Scott R Goldsmith, MD2, Sitong Chen, MPH3, Keith Anderson4, Madison Barton5, Kavya Achanta, PhD6, Kate Farren7, Nathan Perez8, Mareen Kassabian, BS9, Lauren Doan10, Johann Charelus11, Derek Lance12, Alysia Bosworth, BA13, Lanie Lindenfeld14, Matthew Mei I, MD15, Geoffrey Shouse, DO PhD16, L. Elizabeth Elizabeth Budde, MD PhD17, Joo Song, MD18, Alex Francisco Herrera, MD19, F. Lennie Wong, PhD20, Stephen J. Forman, MD21, Saro H Armenian, MD, MPH22
AFFILIATIONS
1 City of Hope National Medical Center, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 City of Hope National Medical Center, Duarte, California, United States
10 City of Hope National Medical Center, Duarte, California, United States
11 City of Hope National Medical Center, Duarte, California, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 City of Hope National Medical Center, Duarte, California, United States
14 City of Hope National Medical Center, Duarte, California, United States
15 City of Hope National Medical Center, Duarte, California, United States
16 City of Hope National Medical Center, Duarte, California, United States
17 City of Hope National Medical Center, Duarte, California, United States
18 City of Hope National Medical Center, Duarte, California, United States
19 City of Hope National Medical Center, Duarte, California, United States
20 City of Hope National Medical Center, Duarte, California, United States
21 City of Hope National Medical Center, Duarte, California, United States
22 City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
Introduction: Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for relapsed or refractory lymphoma and is increasingly incorporated earlier in the treatment paradigm. However, immune effector cell-associated neurotoxicity syndrome (ICANS) remains a clinically consequential complication that can progress rapidly, require intensive supportive care, and contribute to non-relapse morbidity and mortality. Reliable pretreatment biomarkers of ICANS risk remain lacking. Clonal hematopoiesis (CH), characterized by the expansion of hematopoietic stem cell clones harboring somatic mutations, is enriched in cancer patients exposed to genotoxic therapies and may promote dysregulated myeloid inflammation, endothelial dysfunction, and neurovascular injury, processes implicated in ICANS pathogenesis. Although prior studies suggest that CH may influence CAR T-cell toxicity, its association with clinically significant ICANS, high-risk CH features, and cause-specific mortality remains poorly characterized.
Methods: We evaluated 403 consecutive patients who received CAR T-cell therapy for lymphoma between 2017 and 2025 at City of Hope and had available pretreatment peripheral blood DNA samples. Targeted deep sequencing of an 18-gene panel was performed at a median sequencing depth of approximately 1000× to identify CH variants with a variant allele frequency (VAF) ≥2%. The primary toxicity endpoint was clinically significant ICANS (grade ≥2), graded according to ASTCT criteria. Logistic regression models estimated odds ratios (ORs) for the association between CH and grade ≥2 ICANS, adjusting for demographic, disease-related, and treatment-related factors. One-year overall mortality was evaluated using Cox proportional hazards regression, while relapse-related mortality and non-relapse mortality were assessed using Fine-Gray competing-risks regression models according to CH status.
Results: The median age at CAR T-cell infusion was 64.7 years (range, 21.5-85.6 years); 62.5% were male. The cohort was 44.9% non-Hispanic White, 35.5% Hispanic, 15.9% Asian, and 4.7% Black or another race/ethnicity. CAR T-cell products included axicabtagene ciloleucel (61.5%), lisocabtagene maraleucel (19.9%), tisagenlecleucel (6.2%), and brexucabtagene autoleucel (4.5%). Overall, 111 patients (27.5%) harbored at least one CH variant, and 39 (35%) had ≥2 variants. CH prevalence increased with age, from 3.7% among patients aged <45 years, to 13.2% at 45–<55 years, 18.3% at 55–<65 years, 39.6% at 65–<75 years, and 45.2% at ≥75 years (chi-square p<0.001). The most frequently mutated genes were DNMT3A, PPM1D, TET2, and TP53. Overall, 123 patients (30.5%) developed grade ≥2 ICANS following CAR T-cell therapy. ICANS frequency differed across CH subtypes: patients with DNA damage response (DDR)-associated CH, including PPM1D and TP53 mutations, had higher rates than patients non-DDR CH or no CH (51.4% vs. 29.7% vs. 28.1%, respectively; p=0.015). Compared with patients without CH, DDR-CH was associated with 2.7-fold higher odds of ICANS (OR, 2.70, 95% CI, 1.35–5.41), whereas non-DDR CH was not (OR 1.08, 95% CI 0.62–1.90). Greater CH burden and clone size were also associated with higher odds of ICANS: patients with multiple CH variants had an OR of 3.00 (95% CI, 1.53–5.86), and those with VAF >10% had an OR of 2.44 (95% CI, 1.26–4.74) compared with patients without CH. In multivariable analysis, DDR-CH remained independently associated with a nearly threefold higher odds of ICANS (OR 2.95, 95% CI 1.44–6.05; p=0.003). Finally, patients with DDR-CH also had significantly worse 1-year overall survival than those with non-DDR CH or no CH (58.8% vs. 74.3% vs. 76.7%, respectively; p=0.03), driven primarily by a higher risk of non-relapse mortality (subdistribution HR 3.15, 95% CI 1.13–8.77).
Conclusions: In this large, well-characterized cohort of lymphoma patients receiving CAR T-cell therapy, CH was highly prevalent, with DNMT3A, PPM1D, TET2, and TP53 as the most frequently mutated genes. DDR-CH was independently associated with clinically significant ICANS and worse 1-year survival, largely reflecting higher non-relapse mortality. These findings identify DDR-CH as a potential pretreatment biomarker for risk stratification before CAR T-cell therapy and support further investigation of CH-informed surveillance and toxicity-mitigation strategies.
DISCLOSURES
June-Wha Rhee, MD: No relevant conflicts of interest to declare.